title: Brain natriuretic peptide levels and cardiac functional capacity in patients with dyspnea and isolated diastolic dysfunction.
abstract: Diastolic heart failure affects approximately 40%-50% of patients presenting with signs and symptoms of heart failure. The aim of this study was to investigate the relationship between brain natriuretic peptide (BNP) levels and functional capacity in patients admitted with dyspnea and diagnosed with isolated diastolic dysfunction. Fifty-four patients (mean age, 57.4 +/- 8.5 years) with class-2 dyspnea with isolated diastolic dysfunction were enrolled. Serum levels of BNP were measured, and peak oxygen consumption (peak VO(2)), anaerobic threshold (AT), and metabolic equivalent (MET) values were determined with a cardiopulmonary exercise test (CPET). There was a negative correlation between BNP levels and exercise duration (P < 0.05, r = -0.304), AT (P < 0.05, r = -0.380), and number of MET (P < 0.05, r = -0.322) determined by CPET. When patients were divided into 2 groups according to BNP levels; BNP < or = 50 pg/mL (n = 40) versus BNP > 50 pg/mL (n = 14) and analyzed, those with BNP levels > 50 pg/mL had lower peak VO(2) (P = 0.05) and anaerobic threshold (P = 0.01) compared with patients with BNP < or = 50 pg/mL. The results suggest that BNP levels provide an indication about the functional capacity determined by CPET in patients admitted with dyspnea and isolated diastolic dysfunction.
authors: Department of Cardiology, Faculty of Medicine, Baskent University, Ankara, Turkey.
authors: Serpil
authors: S
authors: Eroglu
authors: Aylin
authors: A
authors: Yildirir
authors: Huseyin
authors: H
authors: Bozbas
authors: Alp
authors: A
authors: Aydinalp
authors: Gaye
authors: G
authors: Ulubay
authors: Olcay
authors: O
authors: Eldem
authors: Vahide
authors: V
authors: Simsek
authors: Bulent
authors: B
authors: Ozin
authors: Haldun
authors: H
authors: Muderrisoglu
mesh_terms: D015308:Anaerobic Threshold / Q000502:physiology; D015415:Biomarkers / Q000097:blood; D003971:Diastole; D018450:Disease Progression; D004417:Dyspnea / Q000097:blood / Q000209:etiology / Q000503:physiopathology; D004452:Echocardiography; D004562:Electrocardiography; D005080:Exercise Test; D005260:Female; D005455:Fluorescent Antibody Technique; D005500:Follow-Up Studies; D006352:Heart Ventricles / Q000000981:diagnostic imaging / Q000503:physiopathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009200:Myocardial Contraction / Q000502:physiology*; D020097:Natriuretic Peptide, Brain / Q000097:blood*; D010101:Oxygen Consumption; D011379:Prognosis; D012189:Retrospective Studies; D012720:Severity of Illness Index; D018487:Ventricular Dysfunction, Left / Q000097:blood / Q000150:complications / Q000503:physiopathology
chemical_list: D015415:Biomarkers; D020097:Natriuretic Peptide, Brain